TTK inhibitors exhibit heightened sensitivity toward tumor cells harboring CTNNB1 mutations, implicating CTNNB1 mutations as predictive genetic markers for patient response to TTK inhibitor therapy (Zaman et al., 2017). The gene discussed is TTK; the disease is neoplasm.